Androgenic alopecia has a high incidence, affecting 80% of men and 50% of women in their lifetimes. Although not a life-threatening disease, it can be a deep psychological burden to patients and still lacks an effective and safe treatment. Dutasteride is a5-alpha-reductase inhibitor approved to treat benign prostatic hyperplasia that is also commonly prescribed off-label to treat androgenic alopecia. However, oral dutasteride may cause several severe sexual and neurological sideeffects. Therefore, an effective, localized dutasteride treatment that can reduce the effects of systemic uptake is of great interest. Here, we review available therapies to treat androgenic alopecia focusing on topicalformulations developed thus far-including minoxidil, finasteride, and cosmetics-and on dutasteride-loaded nanocarriers targeting hair follicles.
Keywords: Hair follicles; nanocarriers; nanotechnology; skin; topical delivery.
Dutasteride has gained popularity as a potent alternative to finasteride for treating alopecia. However, developing a safe and effective commercial product is challenging. We seek to identify a follicle-specific delivery vehicle that reduces dutasteride’s systemicabsorption.